StageAcq - P2P | Acquired
About Foundation Medicine
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's initial clinical assay, FoundationOne, is a fully informative genomic profile to identify a patient's individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. FoundationOne is a fully informative genomic profile that complements traditional cancer decision tools and often expands treatment options by matching each patient with targeted therapies that may be relevant to the molecular changes in their tumor. Using next-generation sequencing, FoundationOne interrogates all genes somatically altered in human cancers that are validated targets for therapy or unambiguous drivers of oncogenesis based on current knowledge. It reveals all classes of genomic alterations including base substitutions, insertions, deletions, copy number alterations and select rearrangements. Each patient's genomic profile is reported to the physician matched with targeted therapies and clinical trials that may be relevant based on the molecular blueprint of their tumor. Results are supported by the latest scientific and medical evidence. FoundationOne has been optimized to fit easily into the clinical workflow of a practicing oncologist. It is available for all solid tumors and clinical grade results can be obtained from as little as 50ng of DNA obtained from formalin-fixed, paraffin-embedded tumor tissue samples. FoundationOne is a laboratory-developed test performed at Foundation Medicine's CLIA-certified facility and is currently available for all solid tumor types. On June 18th, 2018, Foundation Medicine was acquired by Roche Holdings.3B.
Missing: Foundation Medicine's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Foundation Medicine's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing Foundation Medicine
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Foundation Medicine in 6 CB Insights research briefs, most recently on Dec 16, 2022.
Expert Collections containing Foundation Medicine
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Foundation Medicine is included in 7 Expert Collections, including Cancer.
Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Health Monitoring & Diagnostics
Companies developing companion diagnostics and technology enabling the development of companion diagnostics. Tagged as #CompanionDx
Foundation Medicine Patents
Foundation Medicine has filed 64 patents.
The 3 most popular patent topics include:
- Transcription factors
- Experimental cancer drugs
Molecular biology, MPEG-2, Genetics, Transaction processing, Viral plant pathogens and diseases
Molecular biology, MPEG-2, Genetics, Transaction processing, Viral plant pathogens and diseases
Latest Foundation Medicine News
Mar 17, 2023
| CAGR 12.5% [PDF Version] News Provided By Share This Article Esoteric Testing Market 1 PORTLAND, OR, UNITED STATE, March 17, 2023 / EINPresswire.com / -- Esoteric Testing Market - Global Outlook and Forecast 2023-2030 is latest research study released by Allied Market Research evaluating the market risk side analysis, highlighting opportunities and leveraged with strategic and tactical decision-making support (2023-2030). The market Study is segmented by key a region that is accelerating the marketization. The report provides information on market research and development, growth drivers, and the changing investment structure of the Global Esoteric Testing Market. Some of the key players profiled in the study are ARUP Laboratories, Baylor Esoteric and Molecular Laboratory, Foundation Medicine, Healius Limited, Laboratory Corporation, Mayo Foundation for Medical Education and Research, OPKO Health, Quest Diagnostics, Sonic Healthcare Limited, and Stanford Clinical Pathology. Click To get FREE SAMPLE PDF (Including Full TOC, Table & Figures): https://www.alliedmarketresearch.com/request-sample/12387 Esoteric testing is a type of medical testing that involves the analysis of rare, complex, or difficult-to-diagnose conditions or diseases. This type of testing is often used when standard laboratory tests have failed to provide a clear diagnosis or when a more specialized approach is needed to determine the underlying cause of a patient's symptoms. Esoteric testing may involve a wide range of tests, including genetic testing, molecular testing, advanced imaging studies, and specialized microbiology and virology tests. These tests often require specialized equipment and expertise, and may be performed by specialized laboratories or academic medical centers. Esoteric testing can be especially helpful in diagnosing rare diseases, identifying genetic mutations or abnormalities, and providing more targeted and personalized treatments for patients. Esoteric Testing Market Statistics: The global Esoteric Testing market size was valued at $20.218 billion in 2020, and is estimated to reach $66.214 billion by 2030, growing at a CAGR of 12.5% from 2021 to 2030. Esoteric Testing Market: Demand Analysis & Opportunity Outlook 2030 Esoteric Testing research study defines market size of various segments & countries by historical years and forecast the values for next 7 years. The report is assembled to comprise qualitative and quantitative elements of Esoteric Testing industry including: market share, market size (value and volume 2017-2021, and forecast to 2030) that admires each country concerned in the competitive marketplace. Further, the study also caters and provides in-depth statistics about the crucial elements of Esoteric Testing which includes drivers & restraining factors that helps estimate future growth outlook of the market. Marketing Communication and Sales Channel Understanding “marketing effectiveness” on a continual basis, help determine the potential of advertising and marketing communications and allow to use of best practices to utilize untapped audience. In order to make marketers make effective strategies and identify why the target market is not giving attention, we ensure the Study is Segmented with appropriate marketing & sales channels to identify potential market size by value & Volume* (if Applicable). Have Any Query? Ask Our Expert @: https://www.alliedmarketresearch.com/purchase-enquiry/12387 The segments and sub-section of Esoteric Testing market is shown below: By Type: Infectious Disease Testing, Oncology Testing, Endocrinology Testing, Genetic Testing, Toxicology Testing, Immunology Testing, Neurology Testing, and Other Testing By Technology: Enzyme-Linked Immunosorbent Assay, Chemiluminescence Immunoassay, Mass-Spectrometry, Real Time Polymerase Chain Reaction, DNA Sequencing, Flow Cytometry, and Other Technologies By End User: Hospital-based Laboratories and Independent and Reference Laboratories Some of the key players involved in the Market are: ARUP Laboratories, Baylor Esoteric and Molecular Laboratory, Foundation Medicine, Healius Limited, Laboratory Corporation, Mayo Foundation for Medical Education and Research, OPKO Health, Quest Diagnostics, Sonic Healthcare Limited, and Stanford Clinical Pathology. Important years considered in the Esoteric Testing study: Historical year – 2017-2021; Base year – 2021; Forecast period** – 2022 to 2030 [** unless otherwise stated] If opting for the Global version of Esoteric Testing Market; then below country analysis would be included: – North America (USA, Canada and Mexico) – Europe (Germany, France, the United Kingdom, Netherlands, Italy, Nordic Nations, Spain, Switzerland and Rest of Europe) – Asia-Pacific (China, Japan, Australia, New Zealand, South Korea, India, Southeast Asia and Rest of APAC) – South America (Brazil, Argentina, Chile, Colombia, Rest of countries etc.) – Middle East and Africa (Saudi Arabia, United Arab Emirates, Israel, Egypt, Turkey, Nigeria, South Africa, Rest of MEA) Key Questions Answered with this Study: 1) What makes Esoteric Testing Market feasible for long term investment? 2) How influencing factors driving the demand of Esoteric Testing in next few years? 3) Territory that may see steep rise in CAGR & Y-O-Y growth? 4) What geographic region would have better demand for product/services? 5) What opportunity emerging territory would offer to established and new entrants in Esoteric Testing market? 6) What strategies of big players help them acquire share in mature market? 7) Know value chain areas where players can create value? 8) What is the impact analysis of various factors in the Global Esoteric Testing market growth? 9) Risk side analysis connected with service providers? Introduction about Esoteric Testing Market Esoteric Testing Market Size (Sales) Market Share by Type (Product Category) Esoteric Testing Market by Application/End Users Esoteric Testing Sales (Volume) and Market Share Comparison by Applications Global Esoteric Testing Sales and Growth Rate (2020-2030) Esoteric Testing Competition by Players/Suppliers, Region, Type, and Application Esoteric Testing (Volume, Value, and Sales Price) table defined for each geographic region defined. Esoteric Testing Players/Suppliers Profiles and Sales Data Key Raw Materials Analysis & Price Trends Supply Chain, Sourcing Strategy and Downstream Buyers, Industrial Chain Analysis ……..and view more in complete table of Contents Procure Complete Report (220+ Pages PDF with Insights, Charts, Tables, and Figures) @ https://www.alliedmarketresearch.com/checkout-final/e088e452626d6b46b7f3f0f9bde4a2c8 Thanks for reading this article; you can also get an individual chapter-wise sections or region-wise report versions like North America, LATAM, Europe, or Southeast Asia. About Us: Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market. David Correa
Foundation Medicine Frequently Asked Questions (FAQ)
When was Foundation Medicine founded?
Foundation Medicine was founded in 2010.
Where is Foundation Medicine's headquarters?
Foundation Medicine's headquarters is located at 150 Second Street, Cambridge.
What is Foundation Medicine's latest funding round?
Foundation Medicine's latest funding round is Acq - P2P.
How much did Foundation Medicine raise?
Foundation Medicine raised a total of $89.74M.
Who are the investors of Foundation Medicine?
Investors of Foundation Medicine include Roche Holding, Yuri Milner, Evan Jones, Bill Gates, Third Rock Ventures and 10 more.
Who are Foundation Medicine's competitors?
Competitors of Foundation Medicine include Genecast, Beacon Biomedical, Tempus, OncoHost, Perthera, Cofactor Genomics, CivaTech Oncology, GENINUS, First Ascent Biomedical, SimBioSys and 31 more.
Compare Foundation Medicine to Competitors
At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.
CellPoint Diagnostics is developing diagnostic, monitoring, and molecular analytical tools for cancer. Its technology captures and analyzes circulating tumor cells ("CTCs") directly from patient blood. Scientific and clinical data have demonstrated that CTCs are derived from the primary tumor, and the assessment of the number of CTCs in the blood has been shown to accurately predict survival for cancer patients.
Predict to Prevent Prognomixs vision is the development of personalized medicine for the early detection of susceptibilities to diseases their complications and individual therapeutic responsiveness using genomic signatures Their initial focus is the development of presymptomatic diagnostic tools of diabetic complications based on genomic signatures aimed at individualized targeted prevention
Akonni Biosystems is a molecular diagnostics (MDx) company that develops, manufactures, and markets integrated molecular diagnostic systems.
XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.
Glycominds Ltd. holds knowledge and experience in the field of glycomics, utilized for the discovery and development of glycan biomarkers which enable high-value medical diagnostics. Glycominds is developing and commercializing a new class of blood tests which allow physicians to detect cancer earlier, predict autoimmune disease progression and decide on therapy regimen.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.